2021_08_NEJM: Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Empagliflozin use in HFpE.
2005_05_NEJM: Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Infliximab induction. Mayo Score for UC
2015_04_NEJM: Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Pentoxifylline did not improve survival in patients with alcoholic hepatitis.
2002_07_Gastroenterology: Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: A randomized, controlled, double-blind trial
IV Erythromycin before emergency endoscopy improves quality of endoscopy
2007_08_Clinical_Infectious_Diseases: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity
Vancomycin and Metronidazole equally effective in C.diff infection
2010_04_NEJM: Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease(SONIC)
2008_02_Lancet: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial
Infliximab and azathioprine combination better than monotherapy with steroids
2007_06_Ann_Intern_Med: Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
Adalimumab as second agent when infliximab non-responding
2019_09_NEJM: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Vedolizumab superior to adalimumab (but not corticosteroid-free clinical remission)
| Study Name | Author and Year | Type of Study and Sample Size | Treatment and Duration | Study Endpoint and Primary Outcome | Results |
|---|---|---|---|---|---|
| Study 1 | Author A (2020) | Randomized Controlled Trial (n=100) | Drug A, 6 months | Endpoint X, Outcome Y | Significant improvement in Y |
| Study 2 | Author B (2019) | Cohort Study (n=200) | Treatment B, 1 year | Endpoint Z, Outcome W | No significant change in W |
| Study 3 | Author C (2021) | Case-Control Study (n=150) | Intervention C, 3 months | Endpoint Y, Outcome Z | Outcome Z improved by 15% |
| Study 4 | Author D (2018) | Cross-Sectional Study (n=250) | Lifestyle change, 6 weeks | Endpoint A, Outcome B | Minor improvement in B |
| Study 5 | Author E (2022) | Meta-Analysis (n=10 studies) | Various, Duration varies | Endpoint C, Outcome D | Overall positive trend in D |